ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,104.97
-0.22%
US Tech 100
17,279.60
-0.18%
Dow Jones
38,144.48
-0.63%
Brent Oil
85.885
-1.60%
Bitcoin
60,914.16
-4.58%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Rocket Pharmaceuticals Inc (RCKT)

  7. Rocket Pharmaceuticals Inc (RCKT) News

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc (RCKT)

NASDAQ
21.53
-0.32
( -1.46% )
Updated: 09:41:27
Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

RCKT News

Official News Only

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 16 2024
RCKT (-1.46%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 16 2024
RCKT (-1.46%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 16 2024
RCKT (-1.46%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 16 2024
RCKT (-1.46%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 16 2024
RCKT (-1.46%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 16 2024
RCKT (-1.46%)

Form 8-K - Current report
Edgar (US Regulatory)
February 13 2024
RCKT (-1.46%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 23 2024
RCKT (-1.46%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 22 2024
RCKT (-1.46%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
January 22 2024
RCKT (-1.46%)

Form 8-K - Current report
Edgar (US Regulatory)
December 13 2023
RCKT (-1.46%)

RCKT Discussion

View Posts
Monksdream Monksdream 4 months ago
RCKT new 52 week high
👍️0
make it happen make it happen 8 months ago
How's it up 38% @ $21.00 PPS when diluting $175,000,000 million @ $16.00??
👍️0
trkyhntr trkyhntr 3 years ago
I have been away at hunting camp for a few weeks, and when I got back I was pleasantly surprised. This puppy has doubled! Any thoughts as to how much more upside there is?
👍️0
ClayTrader ClayTrader 3 years ago
* * $RCKT Video Chart 12-09-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Glider549 Glider549 4 years ago
Check out Seeking Alpha, January 27, article.
Lots of insider buying and Fast Track status.
👍️0
RUSTYJ RUSTYJ 5 years ago
How you figure a lot power , Gravity takes it down
👍️0
investor86 investor86 6 years ago
This got a lot of power!!
👍️0
trkyhntr trkyhntr 6 years ago
This is a new board for this stock. Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.
👍️0

Your Recent History

NASDAQ
RCKT
Rocket Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved